Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders
By Lucy Haggerty
Pharma Deals Review: Vol 2024 Issue 3 (Table of Contents)
Published: 8 Mar-2024
DOI: 10.3833/pdr.v2024.i3.2857 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In yet another move in the protein degradation space, Merck KGaA has signed a strategic discovery research collaboration with C4 Therapeutics focused on two targeted protein degraders against critical oncogenic proteins...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS